Trade Names:Cyproheptadine Hydrochloride- Tablets 4 mg- Syrup 2 mg per 5 mL
Competitively antagonizes histamine at H 1 receptor sites. Also exhibits antiserotonin activity.
The principal metabolite found in the urine is the quaternary ammonium glucuronide conjugate of cyproheptadine.
2% to 20% is excreted in the feces, of which 34% (5.7% of the dose) is unchanged drug. At least 40% is excreted in the urine.
Elimination is diminished in renal insufficiency.
Symptomatic relief of perennial and seasonal allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis due to inhalant allergens and foods; amelioration of allergic reactions to blood or plasma; mild skin manifestations of uncomplicated urticaria and angioedema; cold urticaria; dermatographism; adjunctive anaphylactic therapy.
Appetite stimulation; migraines; nightmares; suppression of vascular headaches.
Newborn or premature infants; breast-feeding mothers; angle-closure glaucoma; stenosing peptic ulcer; symptomatic prostatic hypertrophy; bladder neck obstruction; pyloroduodenal obstruction; elderly, debilitated patients; MAOI therapy; hypersensitivity to cyproheptadine and other drugs of similar structure.
PO Starting dosage, 4 mg 3 times daily. Usual dosage, 4 to 20 mg/day; not to exceed 0.5 mg/kg/day.Children 7 to 14 yr of age
PO 4 mg 2 or 3 times daily (max, 16 mg/day).Children 2 to 6 yr of age
PO 2 mg 2 or 3 times daily (max, 12 mg/day). ( PO Total daily dosage 0.25 mg/kg or 8 mg/m 2 .)
Store at 59° to 86°F. Keep container tightly closed.
May cause additive CNS depressant effects.MAOIs
Anticholinergic effects of cyproheptadine may increase. Concurrent use is contraindicated.
Extrasystoles; hypotension; palpitations; tachycardia.
Confusion; convulsions; disturbed coordination; dizziness; euphoria; excitation; faintness; fatigue; hallucinations; headache; hysteria; insomnia; irritability; nervousness; neuritis; paresthesias; restlessness; sedation and sleepiness (often transient); tremor.
Excessive perspiration; photosensitivity; rash; urticaria.
Acute labyrinthitis; blurred vision; diplopia; dry mouth, nose, and throat; tinnitus; vertigo.
Anorexia; constipation; diarrhea; epigastric distress; nausea; vomiting.
Difficult urination; early menses; urinary frequency; urinary retention.
Agranulocytosis; hemolytic anemia; leukopenia; thrombocytopenia.
Abnormal hepatic function; cholestasis; hepatic failure; hepatitis; jaundice.
Increased appetite; weight gain.
Chest tightness; nasal stuffiness; thickening of bronchial secretions; wheezing.
Anaphylactic shock; chills; edema.
When used for treatment of allergy symptoms, assess allergy symptoms (eg, cough; rhinitis; nasal congestion; sneezing; watery eyes; itching nose, throat, or eyes) before starting therapy and periodically during therapy.
Monitor patient for dizziness and excessive drowsiness. If noted, hold therapy.
Ensure that therapy is periodically reviewed to determine if therapy needs to be continued without change or if a dose change (eg, increase, decrease, discontinuation) is indicated.
Category B .
Undetermined. Contraindicated in breast-feeding women.
Safety and efficacy in children younger than 2 yr of age not established. Contraindicated in newborn or premature infants.
Use with caution because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy; more likely to cause dizziness, sedation, and hypotension. Contraindicated in elderly, debilitated patients.
Use drug with caution in patients with a history of bronchial asthma, increased IOP, hyperthyroidism, CV disease, or hypertension.
May vary from CNS depression to stimulation (especially in children), seizures, GI symptoms, hallucinations, respiratory and cardiac arrest, anticholinergic effects (eg, dilated pupils, dry mouth, flushing).
Copyright © 2009 Wolters Kluwer Health.